Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Exelon for Alzheimer's NDA filing planned for April, firm tells analysts.

Executive Summary

NOVARTIS EXELON NDA FILING FOR ALZHEIMER's SCHEDULED FOR APRIL, the company indicated during a meeting with financial analysts March 19. The company intends to make "one regulatory submission worldwide during April," with the exception of Japan where Phase II development is ongoing. The company projected that market introductions of the acetylcholinesterase inhibitor would begin in the fourth quarter of 1997.



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts